Arsenic is a naturally occurring element widely distributed in the earth’s crust. In the environment, arsenic is combined with oxygen, chlorine, and sulfur to form inorganic arsenic compounds. Arsenic in animals and plants combines with carbon and hydrogen to form organic arsenic compounds.
Breathing high levels of inorganic arsenic can give you a sore throat or irritated lungs.
Ingesting very high levels of arsenic can result in death. Exposure to lower levels can cause nausea and vomiting, decreased production of red and white blood cells, abnormal heart rhythm, damage to blood vessels, and a sensation of “pins and needles” in hands and feet.
Ingesting or breathing low levels of inorganic arsenic for a long time can cause a darkening of the skin and the appearance of small “corns” or “warts” on the palms, soles, and torso.
An estimated 60 million people in Bangladesh are exposed to unsafe levels of arsenic in their drinking water, dramatically raising their risk for cancer and other serious diseases, according to the World Health Organization.
ZIOPHARM Oncology, Inc. today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager for this offering. The co-manager for this offering is JMP Securities LLC. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
More than 20 percent of untreated water samples from 932 public wells across the nation contained at least one contaminant at levels of potential health concern, according to a new study by the U.S. Geological Survey.
ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406).
Pressure treated wooden playground structures do not live up to the bad reputation they have earned as being harmful to children, according to the findings of a new University of Alberta study.
Scientists studying the environmental impact of Hurricane Katrina on the Gulf Coast of Louisiana and the city of New Orleans have revealed the ecological impact and human health risks from exposure to chemical contaminants. The findings, published in a special issue of Environmental Toxicology and Chemistry, demonstrate how Hurricane Katrina caused significant ecological damage by altering coastal chemistry and habitat.
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.
Thermo Fisher Scientific Inc., the world leader in serving science, today opened a global food testing laboratory devoted solely to helping contain costly and life-threatening chemical contamination crises. The Food Safety Response Center, located in Dreieich, Germany, is equipped with state-of-the-art equipment and staffed by world-class chemists who will quickly mobilize to aid governments and businesses facing an unknown food safety threat involving chemical contaminants.
Metal-laden dust and contaminated water, and their health effects, will be the focus of multiple projects for the University of Arizona's Superfund Research Program during the next five years. The National Institutes of Environmental Health Sciences recently notified UA that the Superfund Research Program, funded since 1989, will receive an additional $14 million in grant funding through 2015 to conduct the research.
In an editorial appearing in the Future Medicine journal Aging Health, Dr. Perls applauds the courage and example displayed by the AMA in its recently published assessment of the risks and benefits of growth hormone, testosterone, estrogen and DHEA for anti-aging.
In a competition modeled after TV quiz shows, a team of neurologists from the United States will face Canadian neurologists in the annual "Neurobowl®" on April 11.
Cephalon, Inc. announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. As a result of the acquisition, Mepha is now a wholly-owned subsidiary of Cephalon. The purchase price paid at closing, inclusive of certain closing adjustments, was CHF 662.4 million (or approximately US$615.4 million). The purchase price is also subject to further post-closing working capital and net debt adjustments.
ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.
Cephalon, Inc. announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.
Scientists have identified a potential new approach to treat human African trypanosomiasis (HAT), commonly known as sleeping sickness, which afflicts "tens of thousands of people in sub-Saharan Africa" annually, IRIN reports. By targeting an enzyme the sleeping sickness parasite needs in order to survive, researchers say they can kill it without causing harm to the patient (4/1).
African sleeping sickness or Human African Typanosomiasis is a potentially fatal disease affecting 50 to 70 thousand Africans each year. Carried by the bite tsetse fly this fatal disease is actually caused by a tiny parasite that attacks the nervous system, brain, spinal column resulting in mental confusion and finally death.
Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.
Cephalon, Inc. today announced the company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for its supplemental new drug application for NUVIGIL® (armodafinil) Tablets [C-IV] in the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel.
ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.
CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.